Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Evaluation of the Safety and Efficacy of KL003 Gene Therapy in Patients With Transfusion-dependent β-thalassemia With No Conditioning Regimen
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Listed as NCT06219239, this NA trial focuses on Transfusion-dependent Beta-Thalassemia and remains actively recruiting participants. Sponsored by Institute of Hematology & Blood Diseases Hospital, China, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Recruiting NA
-
Apr 2025 — Sep 2025 [monthly]
Recruiting NA
-
Sep 2024 — Apr 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Recruiting NA
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Hematology & Blood Diseases Hospital, China
- Kanglin Biotech
For direct contact, visit the study record on ClinicalTrials.gov .